|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: OBP2B |
Gene summary for OBP2B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | OBP2B | Gene ID | 29989 |
| Gene name | odorant binding protein 2B | |
| Gene Alias | LCN14 | |
| Cytomap | 9q34.2 | |
| Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | Q9NPH6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 29989 | OBP2B | GSM4909286 | Human | Breast | IDC | 1.74e-47 | 8.72e-01 | 0.1081 |
| 29989 | OBP2B | GSM4909295 | Human | Breast | IDC | 5.28e-10 | 5.98e-01 | 0.0898 |
| 29989 | OBP2B | GSM4909296 | Human | Breast | IDC | 3.32e-03 | -1.04e-01 | 0.1524 |
| 29989 | OBP2B | GSM4909297 | Human | Breast | IDC | 1.57e-03 | -1.01e-01 | 0.1517 |
| 29989 | OBP2B | GSM4909298 | Human | Breast | IDC | 6.76e-49 | 8.52e-01 | 0.1551 |
| 29989 | OBP2B | GSM4909301 | Human | Breast | IDC | 7.43e-04 | -1.04e-01 | 0.1577 |
| 29989 | OBP2B | GSM4909307 | Human | Breast | IDC | 7.01e-03 | -1.04e-01 | 0.1569 |
| 29989 | OBP2B | GSM4909315 | Human | Breast | IDC | 3.32e-03 | -1.02e-01 | 0.21 |
| 29989 | OBP2B | GSM4909319 | Human | Breast | IDC | 3.51e-04 | -1.04e-01 | 0.1563 |
| 29989 | OBP2B | GSM4909321 | Human | Breast | IDC | 1.57e-03 | -1.04e-01 | 0.1559 |
| 29989 | OBP2B | NCCBC3 | Human | Breast | DCIS | 3.32e-03 | -9.49e-02 | 0.1198 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| OBP2B | SNV | Missense_Mutation | rs199938593 | c.424N>A | p.Glu142Lys | p.E142K | Q9NPH6 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| OBP2B | SNV | Missense_Mutation | c.132N>C | p.Arg44Ser | p.R44S | Q9NPH6 | protein_coding | deleterious(0.04) | benign(0.124) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| OBP2B | SNV | Missense_Mutation | novel | c.458N>T | p.Ser153Leu | p.S153L | Q9NPH6 | protein_coding | tolerated(0.25) | benign(0.025) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| OBP2B | SNV | Missense_Mutation | novel | c.38N>T | p.Ala13Val | p.A13V | Q9NPH6 | protein_coding | tolerated(1) | benign(0.007) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| OBP2B | SNV | Missense_Mutation | rs199938593 | c.424N>A | p.Glu142Lys | p.E142K | Q9NPH6 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| OBP2B | SNV | Missense_Mutation | novel | c.277T>A | p.Tyr93Asn | p.Y93N | Q9NPH6 | protein_coding | tolerated(0.22) | benign(0.007) | TCGA-95-7043-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| OBP2B | SNV | Missense_Mutation | novel | c.124N>A | p.Glu42Lys | p.E42K | Q9NPH6 | protein_coding | tolerated(0.69) | benign(0.18) | TCGA-D6-A6ES-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| OBP2B | SNV | Missense_Mutation | novel | c.166G>T | p.Ala56Ser | p.A56S | Q9NPH6 | protein_coding | deleterious(0.05) | possibly_damaging(0.796) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
| OBP2B | SNV | Missense_Mutation | novel | c.251N>T | p.Thr84Met | p.T84M | Q9NPH6 | protein_coding | deleterious(0.05) | probably_damaging(0.998) | TCGA-BR-A4J5-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
| OBP2B | SNV | Missense_Mutation | c.283N>A | p.Gly95Ser | p.G95S | Q9NPH6 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-HJ-7597-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | CR |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |